Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs

被引:73
作者
Olesen, OV
Linnet, K
机构
[1] Inst. for Basic Res. in Psychiatry, Department of Biological Psychiatry, Aarhus University Hospital
来源
JOURNAL OF CHROMATOGRAPHY B | 1997年 / 698卷 / 1-2期
关键词
risperidone; 9-hydroxyrisperidone;
D O I
10.1016/S0378-4347(97)00302-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A HPLC method was developed for determination of risperidone and its therapeutically active main metabolite 9-hydroxyrisperidone in serum. After a single-step liquid-liquid extraction the analytes were separated on a C-18 column and measured by UV detection at 280 nm. Inter-day coefficient of variation was <7% for both compounds at serum levels occurring in patients treated with ordinary doses. Studies of analytical interference showed that the most commonly coadministered antidepressants and benzodiazepines did not interfere. Some conventional low dose neuroleptics and clozapine did interfere, but this is of minor importance, because risperidone is intended as an alternative to these drugs. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 14 条
  • [1] Anderson Cheryl, 1994, Psychopharmacology Bulletin, V30, P88
  • [2] DETERMINATION OF RISPERIDONE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION - APPLICATION TO THERAPEUTIC DRUG-MONITORING IN SCHIZOPHRENIC-PATIENTS
    ARAVAGIRI, M
    MARDER, SR
    VANPUTTEN, T
    MIDHA, KK
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (05) : 447 - 449
  • [3] CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25
  • [4] CHOUINARD G, 1993, CAN J PSYCHIAT, V38, P89
  • [5] RISPERIDONE VERSUS HALOPERIDOL IN THE TREATMENT OF CHRONIC-SCHIZOPHRENIC INPATIENTS - A MULTICENTER DOUBLE-BLIND COMPARATIVE-STUDY
    CLAUS, A
    BOLLEN, J
    DECUYPER, H
    ENEMAN, M
    MALFROID, M
    PEUSKENS, J
    HEYLEN, S
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1992, 85 (04) : 295 - 305
  • [6] ERESHEFSKY L, 1993, CAN J PSYCHIATRY S3, V38, P80
  • [7] Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: Evaluation of a paired approach for psychotropic medication
    GexFabry, M
    BalantGorgia, AE
    Balant, LP
    [J]. THERAPEUTIC DRUG MONITORING, 1997, 19 (01) : 1 - 10
  • [8] RISPERIDONE VERSUS PERPHENAZINE IN THE TREATMENT OF CHRONIC-SCHIZOPHRENIC PATIENTS WITH ACUTE EXACERBATIONS
    HOYBERG, OJ
    FENSBO, C
    REMVIG, J
    LINGJAERDE, O
    SLOTHNIELSEN, M
    SALVESEN, I
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1993, 88 (06) : 395 - 402
  • [9] PHARMACOKINETICS OF THE NOVEL ANTIPSYCHOTIC AGENT RISPERIDONE AND THE PROLACTIN RESPONSE IN HEALTHY-SUBJECTS
    HUANG, ML
    VANPEER, A
    WOESTENBORGHS, R
    DECOSTER, R
    HEYKANTS, J
    JANSEN, AAI
    ZYLICZ, Z
    VISSCHER, HW
    JONKMAN, JHG
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) : 257 - 268
  • [10] DETERMINATION OF RISPERIDONE AND 9-HYDROXYRISPERIDONE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION
    LEMOING, JP
    EDOUARD, S
    LEVRON, JC
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1993, 614 (02): : 333 - 339